• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Lexaria Bioscience Corp. - Warrant (NQ:LEXXW)

    0.0302 -0.0028 (-8.48%)
    Streaming Delayed Price Updated: 3:24 PM EDT, Oct 16, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Lexaria Bioscience Corp. - Warrant

    Lexaria's Formulated Cannabidiol Showed Reduction In Pro-Inflammatory Biomarkers Associated with Heart Diseases
     
    Via Benzinga
    Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride And Cholesterol Levels
    Lexaria Bioscience Corp.’s (NASDAQ: LEXX) (NASDAQ: LEXXW) diabetes animal model study DIAB-A22-1 has been completed and produced at least three positive outcomes including weight loss in 
    Via Benzinga
    Lexaria's DehydraTECH CBD Hypertension Study Dosing Complete With No Serious Adverse Events
    Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) revealed that dosing with Lexaria's DehydraTECH-processed CBD has been completed in its multi-week human clinical hypertension study HYPER-H21-4 
    Via Benzinga
    Lexaria Bioscience (NASDAQ: LEXX) Secures Patent For DehydraTECH To Deliver Antivirals
    This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
    Via Benzinga
    Lexaria Bioscience (NASDAQ: LEXX) Commences Its Most Comprehensive Study To Date
    This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
    Via Benzinga
    Lexaria Bioscience (NASDAQ: LEXX) Issues Update On Human Nicotine Study
    This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
    Via Benzinga
    Lexaria Bioscience Commences DehydraTECH-CBD Epilepsy Research Program
    This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
    Via Benzinga
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.